Brief: Amarin Says Scottish Medicines Consortium Accepts Vazkepa To Help Reduce Cardiovascular Risk
07/08/2023 15:41
Aug 7 (Reuters) - Amarin Corporation PLC AMRN.O :
* AMARIN CORPORATION - SCOTTISH MEDICINES CONSORTIUM ACCEPTS
VAZKEPA (ICOSAPENT ETHYL) TO HELP REDUCE CARDIOVASCULAR RISK FOR
PATIENTS IN SCOTLAND
* AMARIN CORPORATION-WORKING WITH HEALTH BOARDS ACROSS
SCOTLAND TO
SECURE FORMULARY INCLUSION, ENSURE ELIGIBLE POPULATION ACCESS TO
VAZKEPA BY 2023 END
Source text for Eikon: ID:nGNX98y9Xn
Further company coverage: AMRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amarin
See all newsAmarin Corporation PLC reports results for the quarter ended June 30 - Earnings Summary
Ireland's Amarin Q2 revenue falls on lower licensing payments
Amarin Corporation PLC expected to post a loss of 1 cent a share - Earnings Preview
US Supreme Court backs generic drugmaker in 'skinny label' patent case (updated)
US Supreme Court backs generic drugmaker in 'skinny label' patent case